stannic protoporfin + iron sucrose

RBT-1 is a combination drug composed of **stannic protoporfin (Sn protoporphyrin, a tin-containing protoporphyrin)** and **iron sucrose**, developed as a single-dose intravenous preconditioning agent designed to protect against the inflammatory and ischemia-reperfusion damage associated with major surgery, particularly cardiothoracic surgery and acute kidney injury. Its mechanism of action involves **activation of cytoprotective pathways, notably induction of heme oxygenase 1 (HO-1)**, as well as stimulation of anti-inflammatory, antioxidant, and iron-scavenging proteins including interleukin-10 and ferritin. The combination synergistically upregulates cytoprotective genes and blunts adverse outcomes such as acute kidney injury (AKI), ischemia-induced damage, and inflammatory injury. It is being developed by Renibus Therapeutics and has been granted FDA Breakthrough and Fast Track designations. The Phase 2 and ongoing Phase 3 trials have focused on reduction of post-operative complications in cardiothoracic surgery and on protection from acute kidney injury, with significant reductions in ICU time, ventilator time, and 30-day readmission rates reported in Phase 2[2][6].

Brand names

RBT-1RBT1RBT 1

Other names

stannic protoporphyrin + iron sucroseSn protoporphyrin + Fe sucrosestannic protoporfin/iron sucroseFeS/SnPP